Enovis (ENOV) Other Non-Current Liabilities (2010 - 2026)
Enovis' (ENOV) quarterly Other Non-Current Liabilities came in at $393.8 million in Q2 2026, up 9.18% year-on-year from $360.7 million in Q2 2025, and down 7.25% on a QoQ basis from $424.6 million in Q4 2025.
Enovis (ENOV) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Enovis (ENOV) has 17 years of Other Non-Current Liabilities data on file, last reported at $393.8 million in Q2 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 9.18% year-over-year to $393.8 million in Q2 2026; TTM through Apr 2026 was $393.8 million, a 9.18% increase from a year earlier, with the FY2025 full-year figure at $424.6 million, up 61.12% from the prior year.
- Other Non-Current Liabilities for Q2 2026 stood at $393.8 million, down from $424.6 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for ENOV reached as high as $601.0 million in Q2 2022 and fell as low as $130.7 million in Q3 2022.
- Historically, Other Non-Current Liabilities has averaged $289.2 million across 5 years, with a median of $255.2 million in 2024.
- Across the five-year window, Other Non-Current Liabilities slumped 79.17% in 2022 and soared 96.44% in 2024, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $167.0 million in 2022, then rose by 22.27% to $204.2 million in 2023, then increased by 29.06% to $263.5 million in 2024, then jumped by 61.12% to $424.6 million in 2025, then dropped by 7.25% to $393.8 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $393.8 million in Q2 2026, $424.6 million in Q4 2025, and $437.0 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Enovis | 1.50 Bn | 1.47 Bn | 365.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 393.81 Mn |
| Dec 31, 2025 | 424.57 Mn |
| Oct 3, 2025 | 437.01 Mn |
| Jul 4, 2025 | 450.56 Mn |
| Apr 4, 2025 | 360.70 Mn |
| Dec 31, 2024 | 263.52 Mn |
| Sep 27, 2024 | 313.76 Mn |
| Jun 28, 2024 | 255.20 Mn |
| Mar 29, 2024 | 249.05 Mn |
| Dec 31, 2023 | 204.18 Mn |
| Sep 29, 2023 | 159.73 Mn |
| Jun 30, 2023 | 191.55 Mn |
| Mar 31, 2023 | 170.53 Mn |
| Dec 31, 2022 | 166.99 Mn |
| Sep 30, 2022 | 130.67 Mn |
| Jul 1, 2022 | 144.24 Mn |
| Apr 1, 2022 | 601.02 Mn |
| Dec 31, 2021 | 122.16 Mn |
| Oct 1, 2021 | 627.37 Mn |
| Jul 2, 2021 | 600.06 Mn |